DrugPatentWatch Database Preview
Drugs in Development Information for Ipatasertib
Email this page to a colleague
» See Plans and PricingWhat is the drug development status for Ipatasertib?
Ipatasertib is an investigational drug.
There have been 24 clinical trials for Ipatasertib.
The most recent clinical trial was a Phase 1 trial, which was initiated on December 18th 2019.
The most common disease conditions in clinical trials are Breast Neoplasms, Triple Negative Breast Neoplasms, and Prostatic Neoplasms. The leading clinical trial sponsors are Hoffmann-La Roche, Genentech, Inc., and SOLTI Breast Cancer Research Group.
There are twenty-four US patents protecting this investigational drug and three hundred and eighty-nine international patents.
Summary for Ipatasertib
| US Patents | 24 |
| International Patents | 389 |
| US Patent Applications | 49 |
| WIPO Patent Applications | 29 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2019-12-18) |
| Vendors | 45 |
Recent Clinical Trials for Ipatasertib
| Title | Sponsor | Phase |
|---|---|---|
| A Study Of The Pharmacokinetics And Safety Of Ipatasertib In Chinese Participants With Locally Advanced Or Metastatic Solid Tumors. | Hoffmann-La Roche | Phase 1 |
| A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC). | Hoffmann-La Roche | Phase 1 |
| Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients (IPATHER) | Roche Pharma AG | Phase 1 |
Clinical Trial Summary for Ipatasertib
Top disease conditions for Ipatasertib
Top clinical trial sponsors for Ipatasertib
US Patents for Ipatasertib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Ipatasertib | Start Trial | Polymeric nanoparticles and methods of making and using same | Merck Sharp & Dohme Corp. (Rahway, NJ) Pfizer Inc. (New York, NY) | Start Trial |
| Ipatasertib | Start Trial | Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of use | GENENTECH, INC. (South San Francisco, CA) | Start Trial |
| Ipatasertib | Start Trial | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors | Array BioPharma Inc. (Boulder, CO) Covenentech, Inc. (South San Francisco, CA) | Start Trial |
| Ipatasertib | Start Trial | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors | Array Biopharma, Inc. (Boulder, CO) Genentech, Inc. (South San Francisco, CA) | Start Trial |
| Ipatasertib | Start Trial | Combinations of AKT inhibitor compounds and vemurafenib, and methods of use | Genentech, Inc. (South San Francisco, CA) | Start Trial |
| Ipatasertib | Start Trial | Combinations of AKT inhibitor compounds and erlotinib, and methods of use | Genentech, Inc. (South San Francisco, CA) | Start Trial |
| Ipatasertib | Start Trial | Process for making amino acid compounds | Genentech, Inc. (South San Francisco, CA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Ipatasertib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Ipatasertib | European Patent Office | 3119395 | 2034-03-17 | Start Trial |
| Ipatasertib | World Intellectual Property Organization (WIPO) | 2015142605 | 2034-03-17 | Start Trial |
| Ipatasertib | Australia | 2012236135 | 2031-04-01 | Start Trial |
| Ipatasertib | Australia | 2012236138 | 2031-04-01 | Start Trial |
| Ipatasertib | Australia | 2012236144 | 2031-04-01 | Start Trial |
| Ipatasertib | Australia | 2012236166 | 2031-04-01 | Start Trial |
| Ipatasertib | Brazil | 112013025353 | 2031-04-01 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
